Drug Trial Radar · NCT07281079
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Nov 12, 2025
Primary completion
Oct 31, 2027
Study completion Nov 15, 2027
Sponsor
- Lead sponsor
- Neuren Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.
Conditions
- Phelan-McDermid Syndrome
Interventions
NNZ-2591Drug
The study drug will be administered twice daily orally.
PlaceboDrug
The study drug will be administered twice daily orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score.Time frame: Week 13
- Efficacy of NNZ-2591 compared with placebo as measured by the change from baseline in the Vineland Adaptive Behavior Scales-3, Interview version (Vineland-3) receptive communication subdomain raw score.Time frame: Week 13
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Neuren PMS-301 Site #116
Birmingham, Alabama · Recruiting
Neuren PMS-301 Site#122
Glendale, California · Recruiting
Neuren PMS-301 Site #112
Palo Alto, California · Recruiting
Neuren PMS-301 Site#103
San Diego, California · Recruiting
Neuren PMS-301 Site#111
San Rafael, California · Recruiting
Neuren PMS-301 Site #107
Washington D.C., District of Columbia · Recruiting
Neuren PMS-301 Site #105
Atlanta, Georgia · Recruiting
Neuren PMS-301 Site#102
Chicago, Illinois · Recruiting
Neuren PMS-301 Site#109
Chevy Chase, Maryland · Recruiting
Neuren PMS-301 Site#106
Brookline, Massachusetts · Recruiting
Neuren PMS-301 Site#104
Lexington, Massachusetts · Recruiting
Neuren PMS-301 Site #117
Ann Arbor, Michigan · Recruiting
Neuren PMS-301 Site#101
New York, New York · Recruiting
Neuren PMS-301 Site#108
Cincinnati, Ohio · Recruiting
Neuren PMS-301 Site#110
Columbus, Ohio · Recruiting
Neuren PMS-301 Site#115
Houston, Texas · Recruiting
Neuren PMS-301 Site #113
Charlottesville, Virginia · Recruiting
Neuren PMS-301 Site#201
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.